Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Opening Session Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Dec
28
Today In Oncology
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo